3.1 Screening process for eligible literatures
The relevant literatures were searched in 3 main English databases according to the search strategy: PubMed (n = 235), Web of Science (n = 218), Embase (n = 173). After de-duplication (n = 376), the titles and abstracts of the remaining articles (n = 250) were examined and evaluated. 193 articles were rejected for purpose, article type (review, case study, or conference abstract), or irrelevant findings. 57 full-text articles were downloaded, of which 35 studies were rejected after initial analysis due to lack of important data or unsatisfactory quality of NOS scores. Finally, the meta-analysis comprised 22 papers that fully fulfilled the inclusion criteria and quality evaluation. Figure 1 depicts the search flow chart.
3.2 Characteristics of included research projects
Table 1 shows the main characteristics of the 22 included studies. Regarding dietary aspects, a total of five cohort studies were included, and 399,558 individuals were followed up for 5 to 15 years, eventually resulting in 6919 CRC patients. A total of 13 case-control studies involving 11,029 cases and 19,024 controls were included. With respect to serum, two cohort studies were included, with 32,428 participants and, ultimately, 272 patients with CRC. Two case-control studies involving 1073 cases and 1116 controls were included. Studies were published between 2000 and 2019. Eight studies were from European countries, eight from North American countries and six from Asian countries. The major nutrient species studied were carotenoids, lycopene, α-carotene, β-carotene, carotenoids, lutein/zeaxanthin, β-cryptoxanthin, and retinol. The included studies were adjusted for covariates, mainly including: gender, age, smoking, alcohol consumption, family history of CRC and physical activity. The NOS was scored from 6 to 8.
3.3 Association between dietary retinol and various carotenoids and Colorectal cancer risk
3.3.1 β-carotene
We combined a total of 20 sets of data from 11 studies. Comparing high and low intakes, dietary intake of β-carotene reduced the risk of CRC by 11% (OR = 0.89, 95% CI: 0.78-1.03 Figure2A),but the association between the two was not significant( pt =0.113), and due to significant heterogeneity (I2 = 63.2%, p < 0.001), we used a random-effects model for pooled analysis. According to subgroup analysis by tumor type, it can be seen that there is no significant correlation between high intake and the risk of colon cancer (OR = 0.96, 95% CI: 0.84-1.09 Figure3A) and rectal cancer (OR = 1.06, 95% CI: 0.89-1.25 Figure3A). In the subgroup analysis by study type, both the cohort study (OR = 0.95, 95% CI: 0.85-1.07 Figure4A) and the case-control study (OR = 0.81, 95% CI: 0.63-1.05 Figure4A) showed a trend of β-carotene to reduce the risk of CRC, but none of them were significantly associated. Finally, according to gender subgroup analysis, β-carotene intake was not significantly associated with the risk of CRC in female (OR = 0.81, 95% CI: 0.97-1.19 Figure5A), but β-carotene intake was negatively associated with the risk of CRC in male (OR = 0.74, 95% CI: 0.55-0.99 Figure5A).
3.3.2 α-carotene
We combined a total of 10 sets of data from 5 studies. Comparing high and low intakes, dietary intake of α-carotene reduced the risk of CRC by 13% (OR = 0.87, 95% CI: 0.72 – 1.03 Figure2B), but the association between the two was not significant (pt =0.110), and due to significant heterogeneity (I2 = 55.3%, p =0.017), we used a random-effects model for pooled analysis. Subgroup analysis by tumor type showed that high intake was not significantly associated with the risk of colon cancer (OR = 0.96, 95% CI: 0.84-1.09 Figure3B) and rectal cancer (OR = 1.01, 95% CI: 0.76-1.35 Figure3B). In the subgroup analysis by study type, the cohort study (OR = 1.00, 95% CI: 0.86-1.16 Figure4B) showed no significant association between their intake and CRC, and the case-control study (OR = 0.69, 95% CI: 0.47-1.02 Figure4B) showed a trend, but no significant association, of their intake to reduce CRC. Finally, intake of α-carotene tended to reduce CRC in male (OR = 0.71, 95% CI: 0.42-1.22 Figure5B) and female (OR = 0.89, 95% CI: 0.61-1.30 Figure5B) according to gender subgroup analysis, but there was no significant association.
3.3.3 Lycopene
Seven studies were included to combine a total of 13 sets of data. High lycopene (OR = 0.93, 95% CI: 0.81 – 1.07 Figure2C) intake slightly, but not significantly (pt =0.329), reduced CRC risk. Due to significant heterogeneity (I2 = 65.6%, p =0.000), pooling was performed with a random-effects model. Subgroup analysis was performed according to tumor type, study type and gender. Colon cancer (OR = 0.97, 95% CI: 0.85 – 1.10 Figure3C), rectal cancer (OR = 1.11, 95% CI: 0.89 – 1.38 Figure3C), cohort study (OR = 1.04, 95% CI: 0.92 – 1.18 Figure4C), case-control study (OR = 0.82, 95% CI: 0.64 – 1.06 Figure4C), male (OR = 0.88, 95% CI: 0.65 – 1.18 Figure5C), female (OR = 0.96, 95% CI: 0.59 – 1.58 Figure5C). In subgroup analyses, case-control studies showed that lycopene intake was associated with a nonsignificant reduction in CRC risk. There was also a risk reduction effect in women, although it was not significant.
3.3.4 Lutein/Zeaxanthin
Six studies were included and a total of 12 sets of data were combined. There was no significant (pt =0.508) association between high lutein/zeaxanthin (OR = 0.96, 95% CI: 0.87 – 1.07 Figure2D) intake and CRC risk. No significant heterogeneity was found (I2 = 10.6%, p =0.341), which was summarized using a fixed-effect model. Subgroup analysis was performed according to tumor type, study type and gender. Colon cancer (OR = 0.96, 95% CI: 0.84 – 1.09 Figure3D), rectal cancer (OR = 1.09, 95% CI: 0.86 – 1.39 Figure3D), cohort study (OR = 1.04, 95% CI: 0.90 – 1.21 Figure4D), case-control study (OR = 0.89, 95% CI: 0.76 – 1.04 Figure4D), male (OR = 0.89, 95% CI: 0.75 – 1.06 Figure5D), female (OR = 1.08, 95% CI: 0.88 – 1.32 Figure5D). In subgroup analysis, case-control studies showed that lutein/zeaxanthin intake was associated with a non-significant reduction in CRC risk. The risk reduction effect was also present in female, but was not significant.
3.3.5 β-cryptoxanthin
Eight studies were included and a total of 18 sets of data were combined. High β-cryptoxanthin (OR = 0.70, 95% CI: 0.54 – 0.90 Figure2E) intake was able to significantly (pt =0.005) reduce CRC risk by 30%. High heterogeneity was found (I2 = 85.4%, p =0.000), which was combined using the random-effects model. Subgroup analysis was performed according to tumor type, study type, and gender. Colon cancer (OR = 0.95, 95% CI: 0.85 – 1.06 Figure3E), rectal cancer (OR = 0.87, 95% CI: 0.71 – 1.06 Figure3E), cohort study (OR = 0.92, 95% CI: 0.83– 1.03 Figure4E), case-control study (OR = 0.36, 95% CI: 0.19 – 0.72 Figure4E), male (OR = 0.52, 95% CI: 0.30 – 0.89 Figure5E), female (OR = 0.65, 95% CI: 0.43 – 0.98 Figure5E). In subgroup analysis, β-cryptoxanthin intake significantly reduced the risk of CRC, both in male and female.
3.3.6 Total carotenoids
Eight studies were included and a total of 19 sets of data were combined. There was no significant (pt =0.717) association between high carotenoids (OR = 0.97, 95% CI: 0.81-1.15 Figure2F) intake and CRC risk. There was significant heterogeneity (I2 = 69.2%, p =0.000), which was combined using the random-effects model. Subgroup analysis was performed according to tumor type, study type and gender. Colon cancer (OR = 1.05, 95% CI: 0.92 – 1.20 Figure3F), rectal cancer (OR = 1.01, 95% CI: 0.81 – 1.26 Figure3F), cohort study (OR = 1.08, 95% CI: 0.94 – 1.25 Figure4F), case-control study (OR = 0.87, 95% CI: 0.70 – 1.08 Figure4F), male (OR = 1.08, 95% CI: 0.91 – 1.27 Figure5F), female (OR = 1.00, 95% CI: 0.80 – 1.25 Figure5F). No association was found between high carotenoids intake and the risk of CRC in any Subgroup group.
3.3.7 Retinol
Seven studies were included and a total of 15 sets of data were combined. There was no significant (pt = 0.850) association between high retinol (OR = 0.99, 95% CI: 0.89 – 1.10 Figure2G) intake and CRC risk. There was no significant heterogeneity (I2 = 34.5%, p =0.092), and fixed effect model was used for combination. Subgroup analysis was performed according to tumor type, study type and gender. Colon cancer (OR = 1.05, 95% CI: 0.86 – 1.27 Figure3G), rectal cancer (OR = 0.99, 95% CI: 0.89 – 1.11 Figure3G), cohort study (OR = 0.92, 95% CI: 0.60 – 1.43 Figure4G), case-control study (OR = 0.99, 95% CI: 0.89 – 1.11 Figure4G), male (OR = 1.30, 95% CI: 1.02 – 1.66 Figure5G), female (OR =0.79, 95% CI: 0.61 – 1.01 Figure6G). Retinol appeared to play a protective role in women, reducing CRC risk by 21%, although there was no significant association.
3.4 Association of serum retinol and carotenoid levels with Colorectal cancer risk
With regard to serum carotenoids, three studies were included and a total of 11 sets of data were combined. Serum total carotenoids (OR = 0.73, 95% CI: 0.58 – 0.93 Figure6A) were significantly (pt = 0.01) negatively associated with CRC risk. The results showed significant heterogeneity (I2 = 67.5%, p =0.001), which was combined using the random-effects model. The subgroup analysis was performed according to the type of nutrients. Serum α-carotene (OR = 0.61, 95% CI: 0.37 – 0.99 Figure6B) was significantly inversely associated with CRC risk. However, the serum content of β-carotene (OR = 0.83, 95% CI: 0.64 – 1.08 Figure6B), Lycopene (OR = 0.58, 95% CI: 0.22 – 1.54 Figure6B), and β-Cryptoxanthin (OR = 0.69, 95% CI: 0.28 – 1.69 Figure6B), although negatively correlated with CRC risk, was not significant. There was no correlation between serum Lutein/Zeaxanthin (OR = 0.99, 95% CI: 0.63 – 1.56 Figure6B) content and CRC risk.
With regard to serum retinol, three studies were included and a total of four sets of data were combined. High serum retinol (OR = 0.62, 95% CI: 0.26 – 1.49 Figure6C) was inversely associated with CRC risk, but the association was not significant (pt = 0.284). The results showed significant heterogeneity (I2 = 90.8%, p =0.000), and random effects model was used for combination. Subgroup analysis were also performed according to study type. Cohort studies (OR = 1.22, 95% CI: 0.80 – 1.86 Figure6D) showed no association between serum retinol and CRC risk, but case-control studies (OR = 0.29, 95% CI: 0.16 – 0.54 Figure6D) showed a significant inverse association between serum retinol and CRC risk.
3.5 Publication bias and Sensitivity analysis
Due to the reduction in serological studies included, bias testing and sensitivity analysis were not necessary. Therefore, we performed bias test and sensitivity analysis on the combined results of dietary retinol and carotenoids. We used Begg's test as well as Begg's funnel plot to assess publication bias. Begg's test results (Figure7): β-carotene (Pr > | z |=0.417), α-carotene (Pr > | z |=0.721), lycopene (Pr > | z |=0.464), β-Cryptoxanthin (Pr > | z |=0.075), Lutein/Zeaxanthin (Pr > | z |=0.304), Carotenoids (Pr > | z |=0.234), retinol (Pr > | z |=0.692). The results of bias test showed that all funnel plots were symmetrical and (Pr > | z | > 0.05), indicating that no significant publication bias was found in the combined results. Sensitivity analysis (Figure8) of the results was performed and the pooled OR varied in a limited range without significant change after removing each study, indicating that our results were stable. From this, it can be seen that the relevant conclusions we draw are stable and reliable.